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Lysophosphatidic acid (LPA) is a potent lipid mediator that acts on a series of specific G protein-coupled receptors, leading to diverse
biological actions. Lysophosphatidic acid induces cell proliferation, survival and migration, which are critically required for tumour
formation and metastasis. This bioactive lipid is produced by the ectoenzyme lysophospholipase D or autotaxin (ATX), earlier known
as an autocrine motility factor. The ATX–LPA signalling axis has emerged as an important player in many types of cancer. Indeed,
aberrant expression of ATX and LPA receptors occurs during the development and progression of breast cancer. Importantly,
expression of either ATX or LPA receptors in the mammary gland of transgenic mice is sufficient to induce the development of a high
frequency of invasive and metastatic mammary cancers. The focus of research now turns to understanding the mechanisms by which
ATX and LPA promote mammary tumourigenesis and metastasis. Targeting the ATX–LPA signalling axis for drug development may
further improve outcomes in patients with breast cancer.
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Breast cancer is heterogeneous in the development and progression
with patients that have histologically indistinguishable tumours
showing disparate outcomes. Breast cancer is the ‘poster child’ for
personalised therapy with assessment of biomarkers, including
oestrogen receptor (ER), progesterone receptor and human epidermal
growth factor receptor 2 directing patients to specific targeted
therapies. Although it is impossible to fully ascertain the relative
function of earlier detection and improved therapy, mortality rates
for breast cancer have shown remarkable improvement. Despite the
marked improvements in outcomes, 192370 new cases of breast
cancer are predicted last year in the United States, with an expected
death rate of B20% (Jemal et al, 2009). In terms of poor outcomes,
therapy resistance and metastasis both remain as critical challenges.
Therefore, additional therapeutic targets are required to improve
outcomes. As the autotaxin (ATX)–lysophosphatidic acid (LPA)
signalling axis is one of the important survival factors and contributes
to invasion and metastasis (Mills and Moolenaar, 2003), it warrants
investigation both in terms of its function in the initiation and
progression of breast cancer and as a novel therapeutic target.
THE ATX–LPA SIGNALLING AXIS IN CANCER
Membrane lipids are critical for maintaining cell integrity and
supporting multiple cell functions. The lipids themselves can
also function directly as signalling molecules triggering profound
cellular responses through high-affinity and selective cell-
surface receptors. Lysophosphatidic acid (1- or 2-acyl-sn-glycero-3-
phosphate), one of the simplest phospholipids, is produced and
released by many different cell lineages including cancer cells.
Despite its simple structure consisting of a glycerol backbone – a
single fatty acyl chain and a single phosphate – there are many
forms of LPA because of the structure, linkage and location of the
fatty acyl chain on the glycerol backbone. These different forms of
LPA showed distinct activities at different LPA receptors. In the
extracellular fluid, LPA is derived from at least two mechanisms
(Mills and Moolenaar, 2003). First, LPA can be produced by
secretory phospholipase A1 or A2, which hydrolyses the fatty acid
chain of phosphatidic acid at the sn-1 or sn-2 position,
respectively. The other mechanism involves the hydrolysis of
lysophosphatidylcholine by the lysophospholipase D activity of the
ectoenzyme, ATX. Importantly, mice heterozygous for ATX have
plasma LPA levels half that of normal mice (Tanaka et al, 2006;
van Meeteren et al, 2006), suggesting that ATX represents the
biologically relevant pathway determining plasma LPA levels.
The function of ATX in cancer progression was well documen-
ted before the demonstration that it exhibited lysophospholipase D
activity. Autotaxin was identified as autocrine motility factor based
on its function in stimulating chemokinesis and chemotaxis in
melanoma cells (Stracke et al, 1992). Autotaxin was also shown to
increase tumour invasiveness (Nam et al, 2000). Concurrently,
many studies indicated LPA as an important mediator in cancer
progression. Therefore, the discovery that ATX was the important
enzyme producing LPA (Tokumura et al, 2002; Umezu-Goto et al,
2002) linked two independent research fields and catalysed a rapid
advance in our knowledge of the function of the ATX–LPA
signalling axis in cancer. Although ATX is a member of the
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been proposed to mediate its activity as a nucleotide phospho-
diesterase, it is now established that ATX mediates its functions
primarily through production and action of LPA.
Lysophosphatidic acid binds to a series of high-affinity cell-
surface G protein-coupled receptors (GPCRs). There are at least six
GPCRs currently identified as LPA receptors, designated LPA1-6
(Noguchi et al, 2009; Yanagida et al, 2009). Other putative GPCRs
that seem to bind and respond to LPA also have been identified
(Tabata et al, 2007; Murakami et al, 2008); however, further
characterisation as bona fide LPA receptors is still needed. The
best-characterised LPA receptors belong to the endothelial
differentiation gene (EDG) family – LPA1/EDG2, LPA2/EDG4
and LPA3/EDG7 receptors that also include a series of receptors
for the related sphingosine 1-phosphate. Interestingly, at least one
putative LPA receptor is proposed to respond to both LPA and
sphingosine 1-phosphate (Murakami et al, 2008). Recently, these
EDG-family LPA receptors as well as ATX have been implicated in
the development and progression of breast cancer (Liu et al, 2009).
ABERRANT EXPRESSION OF ATX OR THE
EDG-FAMILY LPA RECEPTORS IS SUFFICIENT
TO DRIVE MAMMARY TUMOURIGENESIS
Expression of ATX and the EDG-family LPA receptors is upregu-
lated in many types of cancer. Autotaxin is highly expressed and
correlated with outcomes in a number of cancer lineages, including
glioblastoma (Kishi et al, 2006) and prostate cancer (Nouh et al,
2009). Breast cancer cells express ATX transcripts at a higher level
compared with normal breast epithelium (Yang et al,2 0 0 2 ) .
Interestingly, aberrant expression of ATX markedly enhanced the
aggressiveness of breast cancer cells (Yang et al,2 0 0 2 ) .
Transformation of normal cells may be mediated, in part, by
the upregulation of ATX and the EDG-family LPA receptors.
For example, ATX expression was upregulated B100-fold in
viral Jun oncogene-transformed chick embryonic fibroblasts
(Black et al, 2004). In contrast, the tumour suppressor Nm23-H1
downregulated expression of LPA1 in MDA-MB-435 cells (Horak
et al, 2007). Although the functions of Jun and Nm23-H1 have been
implicated in breast cancer, whether their effects are mediated
through the ATX–LPA axis remains to be ascertained.
The EDG family of LPA receptors are expressed by normal
mammary epithelial cells with aberrant expression of the EDG-
family LPA receptors occurring during breast cancer initiation and
progression. The function of LPA1 in the progression of breast
cancer has been studied more extensively than that of other LPA
receptors. Over-expression of LPA1 is readily observed in breast
cancer cells, suggesting a function in transformation (Witt et al,
2006). Further, a number of breast cancer cell lines express high
levels of LPA1 transcripts (Chen et al, 2007). Manipulation of LPA1
levels or function in breast cancer cell lines altered the ability of
breast cancer cell lines to metastasise to bone (Boucharaba et al,
2004, 2006). We have recently shown that expression of LPA1 in
mammary epithelial cells of transgenic mice was sufficient to
induce the development of mammary cancers with a significant
proportion being invasive and metastatic (Liu et al, 2009).
However, the late onset of tumour development suggests that
additional events must occur for the manifestation of the effects of
transgenic expression of LPA1. Whether these are stochastic events
or are driven by the expression of the LPA1 receptor in a cell-
autonomous manner will require additional exploration. Never-
theless, the combined data validates LPA1 as a high-quality
therapeutic target for drug development and evaluation in breast
cancer.
Less is known about the functions of LPA2 and LPA3 in breast
cancer pathophysiology. Similar to ATX and LPA1, increased
LPA2 expression has been associated with tumour invasiveness
(Kitayama et al, 2004) and breast cancer progression (Li et al,
2009). Transgenic mice over-expressing LPA2 developed mam-
mary tumours with the onset and frequency similar to those
observed in LPA1 transgenic mice (Liu et al, 2009), further
implicating LPA2 in the initiation and progression of breast
cancer. In the central nervous system, LPA1 and LPA2 seem to
mediate redundant functions during brain development (Contos
et al, 2002). The similar phenotypes of transgenic LPA1 and LPA2
mice suggest that these receptors may also mediate similar
functions during breast cancer initiation and progression. Inter-
estingly, LPA2-deficient mice are resistant to the induction of
colon cancer (Lin et al, 2009). Whether LPA2 (or LPA1)-deficient
mice are resistant to the development of breast cancer remains to
be determined.
It is not clear whether expression of LPA3 is altered during
breast cancer progression. Lysophosphatidic acid-3 is less
abundant than LPA1 or LPA2 in breast cancer cells (Chen et al,
2007) and did not seem to be altered in patients with metastatic
breast cancer (Kitayama et al, 2004). However, publicly available
microarray data sets show that poorly differentiated breast cancers
showed higher expression of LPA2 and LPA3 than well-differ-
entiated tumours (Liu et al, 2009). As poorly differentiated breast
cancers have a worsened outcome, it is possible that LPA3
contributes to breast cancer pathophysiology. In support of this
contention, transgenic expression of LPA3 driven by the mouse
mammary tumour virus promoter resulted in tumour development
and metastasis similar to that observed in LPA1 or LPA2
transgenic mice (Liu et al, 2009). Together, the data from
transgenic mouse models indicated that each of the EDG family
of LPA receptors is sufficient to induce invasive and metastatic
tumours when aberrantly expressed in mammary epithelial cells.
MECHANISMS UNDERLYING MAMMARY
TUMOURIGENESIS INDUCED BY ATX AND
THE EDG-FAMILY LPA RECEPTORS
The mechanisms underlying LPA-driven tumour development in
mammary glands remains to be fully elucidated despite extensive
evidence implicating LPA in processes and pathways associated
with tumourigenesis in vitro (Figure 1). Interestingly, tumour
development induced by ATX and the EDG-family LPA receptors
commonly displayed late onset ranging from 8 to 24 months
and occurred in a subpopulation of each transgenic line (Liu et al,
2009). The late onset and stochastic tumour development
suggest that expression of ATX or the EDG-family LPA receptors
cooperates with other events such as secondary mutations to
generate the full tumourigenic phenotype. Indeed, when these
tumours were profiled at both the transcript and protein levels,
they did not form a clear cluster similar to the tight clusters
observed in tumours driven by a number of known oncogenes.
This suggests that multiple different events cooperate with
expression of ATX or the EDG family of receptors in inducing
tumourigenesis. Nevertheless, the tumours did show the activation
of signalling pathways that have been associated with signalling
through LPA receptors in vitro, thus suggesting that LPA signalling
is functional and likely contributes to both the initiation and
progression of the tumours.
A number of important questions require further attention. In
particular, it will be critical to determine whether the effects of
ATX and the EDG-family LPA receptors are cell autonomous
solely through activating process in the transgenic epithelial
cells. Alternatively, ATX or cytokines produced by the transgenic
epithelial cells could alter functions of the stroma, which in turn
contributes to the tumourigenic process. Indeed, in many cases,
tumour development in the ATX and LPA receptor transgenic mice
was preceded by chronic inflammation of the mammary glands
and by elevated levels of circulating cytokines (Liu et al, 2009),
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and stromal cells contributing to tumourigenesis. If this question
is fully addressed, the outcome could suggest a number of different
interventions that would potentially decrease breast cancer
initiation and progression.
It is striking that expression of ATX or each of the EDG-family
LPA receptors resulted in an increased incidence of invasive and
metastatic mammary tumours albeit at different frequencies and
onsets. This suggests that each of the LPA receptor subtypes
mediates common processes sufficient to support the initiation
and progression of tumours. A similar ability to alter tumourigenic
behaviour was also found when expression of the LPA receptors
was elevated in human cancer cell lines. This showed a marked
overlap in the ability of LPA1, LPA2 or LPA3 to initiate tumouri-
genesis despite earlier evidence that each of the LPA receptors
coupled to different signalling pathways (Yu et al, 2008).
Optimal activation of LPA receptors requires ligation by LPA.
Thus, it is likely that the initial step of tumourigenesis induced
by over-expression of the LPA receptors involves endogenous LPA
produced locally by ATX acting on transgenic LPA receptors
on the breast epithelium. Nevertheless, it is possible that the
transgenic LPA receptors are present at sufficiently high levels to
result in a ligand-independent activation through the formation of
homo- or heterodimers in the absence of exogenous LPA. In terms
of the function of the ATX transgene in tumour progression, it is
also likely that the elevated level of LPA activates endogenous LPA
receptors present in the epithelium or surrounding stroma. In
many tissues including breast, LPA levels are regulated through the
balance of its local production by ATX and degradation by lipid
phosphatases. Indeed, transgenic expression of ATX under a liver-
specific promoter was not sufficient to induce mammary or other
tumours despite elevated circulating LPA levels (Pamuklar et al,
2009).
Although ATX and the EDG-family LPA receptors are expressed
in mammary epithelial and stromal cells of both mouse (Liu et al,
2009) and human (Finak et al, 2008), and expression levels are
altered during breast tumourigenesis, little attention has been
given to the mechanisms underlying the tumorigenesis by the
ATX-LPA axis. The stress associated with acquisition of oncogenic
events or loss of tumour suppressors can result in cell death or the
induction of senescence, a process designated ‘oncogenic stress’.
However, the ability of LPA to enhance cell survival may allow
secondary mutations to be ‘fixed’ in the genome and for cells to
continue to proliferation despite ‘oncogenic stress’. In this regard,
it has been shown that activation of LPA2 suppressed p53-
mediated senescence (Kortlever et al, 2008). Lysophosphatidic
acid-2 as well as LPA1 and LPA4 receptors also act cooperatively
with c-Myc oncogene or with the immortalising gene TBX2 to
inhibit apoptosis and induce transformation of embryonic
fibroblasts (Taghavi et al, 2008). Amplification of TBX2 has been
reported in a subset of breast cancer patients (Jacobs et al, 2000);
however, a direct link between LPA signalling and TBX2 levels has
not been shown in breast cancer. Together, it is conceivable that
signalling pathways activated by the ATX–LPA axis initiate
tumour development in breast, in part, by extending cell survival
and allowing cells to be susceptible to the effects of genetic
mutations affecting other genes. If this is the case, the ATX and
LPA receptor transgenic mice may recapitulate the heterogeneity
of tumours found in patients with breast cancer. Indeed, marked
heterogeneity of proteomic and transcriptional profiles was
observed in the tumours from the transgenic mice.
SIGNALLING PATHWAYS ASSOCIATED WITH THE
ATX–LPA SIGNALLING AXIS IN BREAST CANCER
Lysophosphatidic acid elicits many biological effects, including cell
proliferation, survival and migration, that is indeed essential for
the progression of cancer (Mills and Moolenaar, 2003). Lyso-
phosphatidic acid binds to LPA receptors coupled with at least
three subtypes of G proteins, Gq,G i and G12/13, leading to the
activation of multiple downstream signalling pathways (Figure 1).
Mammary tumours derived from transgenic mice expressing ATX
or each of the EDG-family LPA receptors showed upregulation and
activation of downstream pathways associated with receptor
tyrosine kinase signalling, including the PI3K/Akt, p38-MAPK
and ERK/MAPK pathways (Liu et al, 2009). Aberrant receptor
tyrosine kinase function is an important hallmark of breast cancer.
As LPA activates a number of tyrosine kinase receptors by
increasing the rates of release of the cell-surface-tethered growth
factors (Mills and Moolenaar, 2003), it is possible that LPA
receptors promote breast cancer progression through the transac-
tivation of cell-surface tyrosine kinase receptors.
Activation of the Ras/Raf/MAPK pathway has been linked to the
progression of breast cancer (Caldas-Lopes et al, 2009). In
addition, the presence of cyclin D1 was essential for Ras-induced
transformation of mammary epithelial cells (Yu et al, 2001).
Interestingly, upregulation of MAPK and cyclin D1 was found in
mammary tumours induced by ATX or the EDG-family LPA
receptors (Liu et al, 2009). Therefore, LPA may activate the
Ras/MAPK/cyclin D1 pathway to modulate cell-cycle progression
and contribute to the transformation of mammary epithelial
cells. Recent evidence suggests that LPA promotes motility and















Figure 1 Current understanding of breast cancer progression mediated
by ATX–LPA signalling axis. Autotaxin and LPA1–3 receptors are
expressed in mammary glands and can exert multiple effects under
physiological conditions. Lysophosphatidic acid is produce from lysopho-
sphatidylcholine (LPC) by ATX and acts on the EDG-family LPA receptors,
LPA1, LPA2 and LPA3. As an important pathway promoting cell survival,
the ATX–LPA signalling axis may initiate tumourigenesis in breast by allow
cells to be susceptible to other genetic mutations, leading to accumulation
of several aberrant signalling pathways. Indeed, each of these components
of the ATX–LPA signalling axis sufficiently induces tumourigenesis through
upregulation of many signalling pathways, including PI3K, MAPK, Wnt/
b-catenin and ER. In addition, marked increase in the production of several
cytokines by LPA further advance the disease progression by local
inflammation and angiogenesis. The effects of LPA on cytokine production
and blood vessel formation may contribute to the metastasis of breast
tumours to other tissues such as bone.
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be important to determine the relative functions of the Ral
GTPase and the Ras/MAPK/cyclin D1 pathway in the invasion
and metastasis observed in the ATX and LPA receptor transgenic
mice.
The presence of ER is critical for the development and
progression of the majority of breast cancers in human. However,
tumours from most mouse models of breast cancer are ER
negative. Interestingly, a subset of tumours in the transgenic
mouse models of ATX and LPA receptors expressed ER and, in
particular, phosphorylated ER in the nucleus (Liu et al, 2009),
suggesting that ER has a function in the development of LPA-
induced breast cancer at least in the ER-positive tumours.
However, the mechanisms linking ATX and LPA to ER expression
remain unknown. The variable ER expression could relate to the
transformation of a different precursor cell or to differential
regulation of ER expression. The presence of the activated ER in a
subset of the transgenic tumours suggests that combination
therapy targeting ER and ATX–LPA signalling may be effective
for treatment and improve prognosis in patients with ER-positive
breast cancer.
The canonical Wnt/b-catenin signalling is critical for the
maintenance of epithelial progenitor cell populations (Reya and
Clevers, 2005). On the other hand, disruption of this signalling
cascade leads to epithelial transformation and tumourigenesis.
Over-expression of N-terminal-truncated b-catenin in mammary
epithelial cells leads to the development of basal-type carcinoma in
the multiparous mice (Teuliere et al, 2005). Interestingly, it has
been shown that LPA-induced proliferation of HCT116 and
LS174T colon cancer cells require phosphorylation and nuclear
translocation of b-catenin through phosphorylation and inhibition
of GSK-3b (Yang et al, 2005). Activation of Wnt signalling by
LPA has also been shown in breast cancer cells by suppression of
GSK-3b and accumulation of b-catenin in the nucleus (Liu et al,
2009). Therefore, development of breast tumours driven by the
ATX–LPA signalling may require activation of the canonical
Wnt/b-catenin pathway to induce the transformation of mammary
epithelial cells. Conversely, it is possible that the Wnt/b-catenin
signalling regulates the ATX–LPA signalling axis and contributes
to the progression of breast cancer (Malbon, 2005).
BREAST CANCER PROGRESSION MAY INVOLVE
LPA-INDUCED CYTOKINE PRODUCTION
Chronic inflammation is a common observation during cancer
progression and is associated with marked production of cyto-
kines that could further aggravate tumour progression. Indeed,
the ATX–LPA signalling axis has been linked to cytokine
production and chronic inflammation through autocrine or
paracrine mechanisms (Yu et al, 2008; Liu et al, 2009). Elevated
LPA production induced by ATX has also been observed in
chronic hepatitis (Watanabe et al, 2007). Interestingly, LPA2
receptors were required for tumour initiation and progression in
an inflammation-induced mouse model of colon cancer (Lin et al,
2009). Together, this suggests that the production and actions
of LPA have crucial functions in both inflammation and tumour
initiation.
Systemic inflammation has been associated with an increased
risk of breast cancer development (Gadalla et al, 2009) and
metastasis (Das Roy et al, 2009). In addition, local inflammation
leading to chronic mastitis in the mammary gland occurred at a
higher frequency and earlier time point of tumour development in
the ATX and LPA receptor transgenic mice (Liu et al, 2009).
Inflammatory cytokines such as interleukin 6 and interleukin 8
have been implicated in bone metastasis (Boucharaba et al, 2004).
In accord, these cytokines were elevated before the development
of breast tumours and markedly increased in a subset of
tumour-bearing mice (Liu et al, 2009). Thus, production
of inflammatory cytokines as a consequence of expression of
ATX and LPA receptors in the transgenic mice may contribute to
tumourigenesis by inducing sustained inflammation of
mammary glands (Figure 1). Whether the induction of inflamma-
tion and tumourigenesis is orthologous events or whether the
ATX–LPA signalling axis in epithelial cells results in the activation
of inflammatory cells that contribute to tumourigenesis
will need to be analysed through experimental interventions.
Further, it will be critically important to determine whether the
activation of ATX and LPA receptors induces production of
inflammatory cytokines in a cell-autonomous manner or through
bidirectional interaction between the epithelial cells and the
microenvironment.
The ‘angiogenic switch’ has been proposed to represent an
important transition from the benign to the malignant state. The
ATX and LPA stimulate production of many angiogenic factors
including vascular endothelial growth factor in ovarian cancer cells
(Hu et al, 2001; Lee et al, 2006; Ptaszynska et al, 2008). In breast
tumours driven by ATX and LPA receptors, levels of vascular
endothelial growth factor were also increased before the presence
of detectable tumours with levels increasing in mice with extant
tumours (Liu et al, 2009). Thus, the ATX–LPA axis may contribute
to the angiogenic switch in breast cancer that leads to tumour
invasion and metastasis.
FUTURE PROSPECTS FOR THE ATX–LPA
SIGNALLING AXIS AS A TARGET IN BREAST CANCER
As we first implicated LPA as a potential mediator in breast
tumourigenesis by studies of breast cancer cell lines (Xu et al,
1995), many subsequent studies have combined to establish an
important function for the ATX–LPA axis in the development and
progression of breast cancer. The demonstration that expression of
ATX and the EDG-family LPA receptors is sufficient to induce
mammary tumours suggests that the ATX–LPA signalling axis
is a novel target in breast cancer and potentially other cancer
lineages. Multiple approaches targeting specific components of
the ATX–LPA signalling axis are in preclinical development.
Silencing LPA1 expression by siRNA or inhibiting LPA function
with small molecule inhibitors effectively suppressed cytokine
production and bone metastasis of breast cancer cell lines
(Boucharaba et al, 2006). Interestingly, LPA analogues, which
have dual activities as ATX and LPA receptor inhibitors
suppressed migration of breast cancer cells in vitro as well as
tumour growth in vivo (Zhang et al, 2009). In other systems,
selective ATX inhibitors reduced metastasis of melanoma cells to
lung (Baker et al, 2006). These and other ATX inhibitors should be
tested in breast cancer models. Indeed, these studies are underway
in the transgenic mouse models. In addition, a monoclonal
antibody that specifically binds and neutralises LPA has been
developed and is in late preclinical development (http://
www.lpath.com). Together, these approaches should be evaluated
as potential additions to the armamentarium for the treatment
of breast cancer.
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